Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Management of glomerular proteinuria: a commentary.

Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA.

J Am Soc Nephrol. 2003 Dec;14(12):3217-32. Review.

2.

Renoprotection: one or many therapies?

Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH.

Kidney Int. 2001 Apr;59(4):1211-26. Review.

4.

Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.

Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.

Am J Kidney Dis. 2008 Sep;52(3):475-85. doi: 10.1053/j.ajkd.2008.03.008. Epub 2008 May 12.

PMID:
18468748
5.

Therapeutic measures in proteinuric nephropathy.

Praga M.

Kidney Int Suppl. 2005 Dec;(99):S137-41. Review.

PMID:
16336567
6.

[Are all antihypertensive drugs renoprotective?].

Wolf S, Risler T.

Herz. 2004 May;29(3):248-54. Review. German.

PMID:
15167950
7.

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD.

Am J Kidney Dis. 2006 Jul;48(1):8-20. Review.

PMID:
16797382
8.

Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.

Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S.

Clin Nephrol. 2005 Jul;64(1):35-40.

PMID:
16047643
9.

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.

Kunz R, Friedrich C, Wolbers M, Mann JF.

Ann Intern Med. 2008 Jan 1;148(1):30-48. Epub 2007 Nov 5.

PMID:
17984482
10.

Comparison of histopathological characteristics of allograft biopsy between responder and non-responder to antiproteinuric effect of angiotensin-converting enzyme inhibitor (ACEI).

Namba Y, Moriyama T, Kyo M, Oka K, Kokado Y, Shi Y, Imamura R, Ichimaru N, Okuyama A, Takahara S.

Clin Transplant. 2004;18 Suppl 11:29-33.

PMID:
15191370
11.

The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).

Luno J, Praga M, de Vinuesa SG.

Curr Pharm Des. 2005;11(10):1291-300. Review.

PMID:
15853685
12.

Titrating for antiproteinuric effect: the clue to renoprotection?

Navis G, de Zeeuw D.

J Hum Hypertens. 1996 Oct;10(10):669-73. Review.

PMID:
9004092
13.

Reversal of proteinuric renal disease and the emerging role of endothelin.

Barton M.

Nat Clin Pract Nephrol. 2008 Sep;4(9):490-501. doi: 10.1038/ncpneph0891. Epub 2008 Jul 22. Review.

PMID:
18648345
14.

[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.

Nefrologia. 2008;28 Suppl 3:39-48. Spanish.

15.

Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN).

Remuzzi G, Chiurchiu C, Ruggenenti P.

Kidney Int Suppl. 2004 Nov;(92):S90-6. Review.

16.

Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results.

Lea JP, Brown DT, Lipkowitz M, Middleton J, Norris K; AASK Study Group.

Am J Cardiovasc Drugs. 2003;3(3):193-200. Review.

PMID:
14727931
17.

Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.

Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S250-4. Review.

18.

Antihypertensive therapy in the presence of proteinuria.

Sarafidis PA, Khosla N, Bakris GL.

Am J Kidney Dis. 2007 Jan;49(1):12-26. Review.

PMID:
17185142
19.

Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.

Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK.

Am J Kidney Dis. 2008 May;51(5):724-31. doi: 10.1053/j.ajkd.2007.12.038. Epub 2008 Apr 3.

PMID:
18436082
20.

Clinical benefits of slowing the progression of renal failure.

Locatelli F, Del Vecchio L, Pozzoni P.

Kidney Int Suppl. 2005 Dec;(99):S152-6. Review.

PMID:
16336569

Supplemental Content

Support Center